Table 3.
Clinical characterization of the study population in PSM.
| Variables | Total (N = 544) | Combined treatment (N = 272) | Conventional treatment (N = 272) | P valuesa |
|---|---|---|---|---|
| Sex [male, N(%)] | 320 (58.8) | 161 (59.2) | 159 (49.7) | 0.862 |
| Age (years) | 65.35 ± 11.13 | 65.31 ± 11.24 | 65.42 ± 11.04 | 0.905 |
| BMI (Kg*m-2) | 25.53 ± 1.71 | 25.55 ± 1.78 | 25.51 ± 1.65 | 0.799 |
| Physical activity [Hgih, N(%)] | 236 (43.4) | 120 (44.1) | 116 (42.6) | 0.729 |
| Smoking [N(%)] | 348 (64.0) | 173 (63.6) | 175 (64.3) | 0.858 |
| Alcohol consumption [N(%)] | 271 (49.8) | 144 (52.9) | 127 (46.7) | 0.145 |
| Hypertension [N(%)] | 213 (39.2) | 104 (38.2) | 109 (40.1) | 0.661 |
| Diabetes [N(%)] | 185 (34.0) | 90 (33.1) | 95 (34.9) | 0.651 |
| Hyperlipemia [N(%)] | 177 (32.5) | 83 (30.5) | 94 (34.6) | 0.314 |
| Carotid atherosclerosis [N(%)] | 177 (32.5) | 93 (34.2) | 84 (30.9) | 0.410 |
| Stroke [N(%)] | 59 (10.8) | 29 (10.7) | 30 (11.0) | 0.890 |
| Renal insufficiency [N(%)] | 18 (3.3) | 9 (3.3) | 9 (3.3) | >0.999 |
| Antiplatelet [N(%)] | 475 (87.3) | 240 (88.2) | 235 (86.4) | 0.519 |
| Antianginal [N(%)] | 85 (15.6) | 39 (14.3) | 46 (16.9) | 0.408 |
| Nitrate ester [N(%)] | 117 (21.5) | 54 (19.9) | 63 (23.2) | 0.348 |
| ACEI/ARB [N(%)] | 239 (43.9) | 117 (43.0) | 122 (44.9) | 0.666 |
| β-blockers [N(%)] | 279 (51.3) | 143 (52.6) | 136 (50.0) | 0.548 |
| CCB [N(%)] | 153 (28.1) | 77 (28.3) | 76 (27.9) | 0.924 |
| Anticoagulant [N(%)] | 43 (7.9) | 23 (8.5) | 20 (7.4) | 0.634 |
| Lipid-lowering [N(%)] | 493 (90.6) | 247 (90.8) | 246 (90.4) | 0.883 |
| Gensini score | 22.00 (10.00, 47.00) | 23.00 (12.00, 50.00) | 22.00 (10.00, 45.50) | 0.509 |
| Hcy (μmol*L-1) | 14.77 ± 6.60 | 14.68 ± 7.20 | 14.87 ± 5.95 | 0.731 |
| LDL-C (mmol*L-1) | 2.37 ± 0.72 | 2.36 ± 0.73 | 2.38 ± 0.71 | 0.710 |
| Lp-a (mg*L-1) | 119.57 (56.12, 222.66) | 115.88 (56.12, 195.15) | 129.85 (53.07, 235.56) | 0.253 |
| HbA1c (%) | 6.27 ± 2.19 | 6.17 ± 1.37 | 6.36 ± 2.78 | 0.320 |
| Urea (mmol*L-1) | 17.32 ± 7.65 | 17.20 ± 8.84 | 17.44 ± 6.26 | 0.716 |
| Scr (mg*dL-1) | 0.96 (0.81, 1.11) | 0.92 (0.81, 1.09) | 0.98 (0.80, 1.12) | 0.075 |
| SAQ of Exertional capacity | 60.17 ± 15.96 | 60.67 ± 16.22 | 59.67 ± 15.70 | 0.467 |
| SAQ of Anginal stability | 50.36 ± 22.49 | 50.80 ± 23.47 | 49.92 ± 21.50 | 0.646 |
| SAQ of Anginal frequency | 74.63 ± 22.15 | 75.50 ± 26.51 | 73.76 ± 16.69 | 0.360 |
| SAQ of Disease perception | 64.69 ± 17.17 | 65.03 ± 18.55 | 64.35 ± 15.70 | 0.644 |
| SAQ of Treatment satisfaction | 79.93 ± 11.71 | 79.91 ± 11.80 | 79.96 ± 11.64 | 0.963 |
| CVE [N(%)] | 42 (7.7) | 16 (5.9) | 26 (9.6) | 0.108 |
a
Differential analysis of the data between the “Combined treatment” and “Conventional treatment” groups.